SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/07/21 Neogen Corp. 8-K:2,9 1/04/21 11:135K Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 23K 2: EX-99.1 Miscellaneous Exhibit HTML 10K 7: R1 Document and Entity Information HTML 41K 9: XML IDEA XML File -- Filing Summary XML 12K 6: XML XBRL Instance -- d102117d8k_htm XML 12K 8: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.LAB XBRL Labels -- neog-20210104_lab XML 47K 5: EX-101.PRE XBRL Presentations -- neog-20210104_pre XML 30K 3: EX-101.SCH XBRL Schema -- neog-20210104 XSD 12K 10: JSON XBRL Instance as JSON Data -- MetaLinks 10± 17K 11: ZIP XBRL Zipped Folder -- 0001193125-21-003464-xbrl Zip 11K
8-K |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) i January 4, 2021
NEOGEN CORPORATION
(Exact name of registrant as specified in its charter)
i Michigan | i 0-17988 | i 38-2367843 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
i 620 Lesher Place i Lansing, i Michigan | i 48912 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code i 517- i 372-9200
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.01 | Completion of Acquisition of Disposition of Assets |
On January 4, 2021, Neogen Corporation announced that it had acquired Ireland-based Megazyme, Ltd. — a supplier of analytical solutions used by quality control laboratories in the global food and beverage industries. Megazyme, founded in 1988, develops and refines analytical methods used to measure the carbohydrates and enzymes in grain, cereal, wine, dairy and other food products, that affect quality. Megazyme will continue to operate as a standalone business in Bray, Ireland, and will be managed through Neogen’s European operations in Scotland.
A copy of the press release is attached as Exhibit 99.1 to this report. This Form 8-K and the attached exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not incorporated by reference into any filing of the Registrant, whether made before or after the date of this report, regardless of any general incorporation language in the filing.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
99.1 | ||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NEOGEN CORPORATION | ||||||
(Registrant) | ||||||
Date: January 6, 2021 | ||||||
Steven J. Quinlan | ||||||
Vice President & CFO |
This ‘8-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed as of: | 1/7/21 | 4 | ||
Filed on: | 1/6/21 | 4 | ||
For Period end: | 1/4/21 | |||
List all Filings |